Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today
Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today. The CSL Group reported a 3.7% rise in sales with total revenue (includes royalties) increasing by 4.8% to US$2.691 billion. The company did take a hit in this result due to the one-off US antitrust class action litigation settlement of US$64 million. CSL will pay a half year dividend of US$0.53. The said it expects FY14 after tax profit growth of around 7% and CSL will continue its current A$950 million share buyback that is now 22% completed. Watch full report here:
most popular
Equities
Jun Bei Liu: Demand couldn't be higher for this biotech
Chris Conway,
Livewire Markets
Equities
The quirky trend to add to your recession ready portfolio
Sara Allen,
Livewire Markets